Play on the pin's page

Regeneron Pharmaceuticals: upcoming dates

Upcoming dates: 3 · All pins: 8

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Upcoming

Health10/05/2026@EconDesk

Regeneron's Next Results: Q3 2026, Expected 30 October

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

Regeneron's Next Results: Q3 2026, Expected 30 October

Starts 10/30/2026SCHEDULED77% CONFIDENCEin 22 days

Regeneron's^[2] 24 September 2026 release (GlobeNewswire copy on Finviz^[1]) says it 'will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open' with a call at 8:30 AM Eastern Time.

Regeneron said on 24 September 2026 it will report third-quarter 2026 financial and operating results on Friday 30 October before US markets open, with a conference call and webcast at 8:30 a.m. Eastern.

Health09/20/2026@HealthDesk

REGN7508's Phase 3 Trial in Symptomatic Venous Thromboembolism Reads Out

Regeneron PharmaceuticalsEastview, Mount Pleasant, United States

Starts 05/17/2027ESTIMATED50% CONFIDENCEin 221 days

ClinicalTrials.gov^[1] lists 2027-05-17 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in symptomatic venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Recent

Health10/05/2026@EconDesk

Regeneron Q2 2026: Revenue Up 17% to US$4.3 Billion

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

Regeneron Q2 2026: Revenue Up 17% to US$4.3 Billion

Starts 07/30/2026CONFIRMED82% CONFIDENCE70 days ago

The GlobeNewswire release is datelined 'TARRYTOWN, N.Y., July 30, 2026' and begins 'today announced financial results for the second quarter of 2026'; the finviz^[2] and 1stOncology^[3] copies are dated the same day.

On 30 July 2026 Regeneron reported second-quarter revenue of US$4.3 billion, up 17%, with Dupixent global sales of US$6.0 billion, EYLEA HD US sales of US$596 million and non-GAAP EPS of US$14.29.

Health10/05/2026@HealthDesk

FDA Approves Otarmeni, the First Gene Therapy for Genetic Hearing Loss

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

FDA Approves Otarmeni, the First Gene Therapy for Genetic Hearing Loss

Starts 04/23/2026CONFIRMED83% CONFIDENCE168 days ago

Regeneron's^[4] release (published by HearingTracker^[1], 'Published on Apr 23, 2026') says the FDA 'has granted accelerated approval for Otarmeni'; MedCity News^[3], dated April 23, 2026, calls it 'The FDA decision announced Thursday'.

On 23 April 2026 the FDA granted accelerated approval to Regeneron's Otarmeni (lunsotogene parvec-cwha, formerly DB-OTO), the first gene therapy for OTOF-related hearing loss, which Regeneron will supply free of charge in the US.

Health10/05/2026@HealthDesk

FDA Lets EYLEA HD Be Dosed Every 20 Weeks for Wet AMD and DME

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

FDA Lets EYLEA HD Be Dosed Every 20 Weeks for Wet AMD and DME

Starts 04/02/2026CONFIRMED83% CONFIDENCE189 days ago

The GlobeNewswire release is datelined 'TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE)' and says the FDA 'has approved the extension of dosing intervals for EYLEA HD up to every 20 weeks'.^[1]

On 2 April 2026 the FDA approved extending EYLEA HD dosing intervals to every 20 weeks, up to 5 months, for wet age-related macular degeneration and diabetic macular edema after a year of successful response.

Health10/05/2026@HealthDesk

Dupixent Becomes the First Approved Treatment for Allergic Fungal Rhinosinusitis

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

Dupixent Becomes the First Approved Treatment for Allergic Fungal Rhinosinusitis

Starts 02/24/2026CONFIRMED84% CONFIDENCE226 days ago

The GlobeNewswire release is datelined 'TARRYTOWN, N.Y. and PARIS, Feb. 24, 2026' and says the FDA 'has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS)'.^[1]

On 24 February 2026 the FDA approved Dupixent for adults and children aged 6 and older with allergic fungal rhinosinusitis who have had sino-nasal surgery, the first medicine approved for the condition and the drug's ninth US indication area.

Health10/05/2026@HealthDesk

FDA Approves EYLEA, Regeneron's First Eye Drug, for Wet AMD

Regeneron Tarrytown Campus, Eastview, Town of Greenburgh, Westchester County, New York, United States

Regeneron Pharmaceuticals

FDA Approves EYLEA, Regeneron's First Eye Drug, for Wet AMD

Starts 11/18/2011CONFIRMED82% CONFIDENCE14.9 years ago

Regeneron's^[4] PRNewswire release is datelined 'TARRYTOWN, N.Y., Nov. 18, 2011' and FierceBiotech^[1] posted it 'Nov 18, 2011 5:56pm'; Wikipedia's^[2][3] aflibercept page also dates the approval to November 2011.

On 18 November 2011 the FDA approved Regeneron's EYLEA (aflibercept) Injection for wet age-related macular degeneration, dosed every eight weeks after three monthly injections, in a Priority Review.

Regeneron Pharmaceuticals: upcoming dates

Upcoming

Regeneron's Next Results: Q3 2026, Expected 30 October

Related tags

Regeneron Pharmaceuticals: upcoming dates

Upcoming

Regeneron's Next Results: Q3 2026, Expected 30 October

Related tags

REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out

REGN7508's Phase 3 Trial in Symptomatic Venous Thromboembolism Reads Out

Recent

Regeneron Q2 2026: Revenue Up 17% to US$4.3 Billion

FDA Approves Otarmeni, the First Gene Therapy for Genetic Hearing Loss

FDA Lets EYLEA HD Be Dosed Every 20 Weeks for Wet AMD and DME

Dupixent Becomes the First Approved Treatment for Allergic Fungal Rhinosinusitis

FDA Approves EYLEA, Regeneron's First Eye Drug, for Wet AMD